key: cord-0869474-8pq75nvd
authors: Barchuk, A.; Shirokov, D.; Sergeeva, M.; Tursun-zade, R.; Dudkina, O.; Tychkova, V.; Barabanova, L.; Skougarevskiy, D.; Danilenko, D.
title: Evaluation of the performance of SARS-CoV-2 antibody assays for the longitudinal population-based study of COVID-19 spread in St. Petersburg, Russia
date: 2021-04-07
journal: nan
DOI: 10.1101/2021.04.05.21254712
sha: 23c325a8eae90eea2b11e20ea589a0e23d1c3f4b
doc_id: 869474
cord_uid: 8pq75nvd

Background: An evident geographical variation in the SARS-CoV-2 spread requires seroprevalence studies based on local tests with robust validation against already available antibody tests and neutralization assays. This report summarizes the evaluation of antibody tests used in the representative population-based serological study of SARS-CoV-2 in Saint Petersburg, Russia. Methods: We used three different antibody tests throughout the study: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS-CoV-2 IgG, Enzyme-linked immunosorbent assay (ELISA) CoronaPass total antibodies test, and ELISA SARS-CoV-2-IgG-EIA-BEST. Clinical sensitivity was estimated with the SARS-CoV-2 PCR test as the gold standard and specificity in pre-pandemic sera samples using the cut-off recommended by manufacturers. Paired and unpaired serum sets were used. Measures of concordance were also calculated in the seroprevalence study sample against the microneutralization test (MNA). Findings: Sensitivity was equal to 91.1% (95% CI: 78.8-97.5) and 90% (95% CI: 76.4-96.4) for ELISA Coronapass and ELISA Vector-Best respectively. It was equal to 63.1% (95% CI (50.2-74.7) for CMIA Abbott. Specificity was equal to 100% for all the tests. Comparison of ROCs for three tests has shown lower AUC for CMIA Abbott, but not for ELISA Coronapass and CMIA Abbott. The cutoff SC/O ratio of 0.28 for CMIA-Abbott resulted in a sensitivity of 80% at the same full level of specificity. In less than one-third of the population-based study participants with positive antibody test results, we detected neutralizing antibodies in titers 1:80 and above. There was a moderate correlation between antibody assays results and MNA. Interpretation: Our validation study encourages the use of local antibody tests for population-based SARS-CoV-2 surveillance and sets the reference for the seroprevalence correction. Available tests are sensitive enough to detect antibodies in most individuals with previous positive PCR tests with a follow-up of more than 5 months. The Abbott Architect SARS-CoV-2 IgG's sensitivity can be significantly improved by incorporating a new cut-off. Relying on manufacturers' test characteristics for correction of reported prevalence estimates may introduce bias to the study results.

SARSCoV2 seroprevalence studies have proved to be a valuable tool in the assessment of the COVID19 pandemic dynamics [1] [2] [3] . However, researchers have raised several concerns regarding the nonresponse bias, the nonrepresentative sampling, and the use of nonvalidated tests for SARSCoV2 antibodies detection [4] . The first two issues can be addressed by appropriate 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 7, 2021. ; https://doi.org/10.1101/2021.04.05.21254712 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. study design and population sampling strategies [ 5; 6] . The latter problem requires the assessment of sensitivity and specificity of antibody assays to guide the correction of serological study results [7] [8] [9] [10] [11] . Additional requirements for antibody tests are being lodged for longitudinal serologic studies, but manufacturers rarely report the evaluation of the longterm test performance, e.g., decreased longterm sensitivity is an issue that could bias the evaluation of immune response durability [ 12; 13 ]. An evident geographical variation in the spread of SARSCoV2 requires local seroprevalence studies [14] . The use of locally available tests from national manufacturers can be convenient but often comes at the expense of test performance [3] . Local tests require robust validation against the benchmark of already available antibody tests and microneutralization assays using sera samples from cases confirmed by PCR and from healthy donors.

Longterm performance of antibody tests is key to understanding the antibody kinetics. Previous validation studies have shown significant changes in the sensitivity of certain antibody tests in the longer followup [15] . This report summarizes the validation of antibody tests used in the representative populationbased serological study of SARSCoV2 in St. Petersburg, Russia, a densely populated city with more than 5 million inhabitants making it the fourth largest city in Europe [6] . We aimed at establishing test specificity (Sp) and sensitivity (Se) to correct estimates obtained through populationbased seroprevalence study.

Information about the corresponding seroprevalence study in St. Petersburg is available in the detailed report [6] . In brief, we obtained a representative population sample through phone by using randomdigit dialling. The study started in May 2020. The first report was publicly available in August 2020. This study is underway and includes three rounds of blood sample collection with more than 2,500 participants.

We used three different antibody tests throughout the study: 1) chemiluminescent microparticle immunoassay Abbott Archi tect SARSCoV2 IgG on the Abbott ARCHITECT® i2000sr platform (Abbott Laboratories, Chicago, USA), detecting im munoglobulin class G (IgG) antibodies to the nucleocapsid protein of SARSCoV2 with the signal/cutoff (S/CO) ratio of 1. Test performance for CMIA Abbott is available from the manufacturer materials (Se=100%, Sp=99.6%). It was also eval uated in numerous independent studies [9; [16] [17] [18] . ELISA Coronapass test manufacturer provides information on its official website (Se=98.7%, Sp=100%). ELISA VectorBest sensitivity and specificity is reported reported in one study published in 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 7, 2021. ; https://doi.org/10.1101/2021.04.05.21254712 doi: medRxiv preprint Russian (Se=100%, Sp=99.8%) [19] .

We used CMIA Abbott and ELISA Coronapass for the first publication of a populationbased seroprevalence study in May June 2020 [6] . The first round of the study analysis showed that the use of ELISA Coronapass results in a slightly higher seroprevalence estimation. It was the initial reason for the independent validation of the test performance.

In the sensitivity assessment, we also used CMIA Elecsys AntiSARSCoV2, manufactured by Roche Diagnostics GmbH, Mannheim, Germany (CMIA Roche, S/CO ratio of 1.0 for positivity, Se=99.5%, Sp=99.8%; diagnostics.roche.com/ru/ ru/products/params/elecsys-anti-sars-cov-2.html).

For the sensitivity assessment, we obtained 92 serum samples collected from the staff of "Scandinavia" clinic as part of routine antibody monitoring carried out in the clinic. Serum samples were obtained for individuals who reported positive PCR tests for SARSCoV2 RNA. The median time between a positive PCR test result and blood draw for antibody test was equal to 21

For the specificity assessment, prepandemic human sera samples were obtained from healthy blood donors collected by

Smorodintsev Research Institute of Influenza through routine influenza surveillance in different cities across Russia. Sera samples are collected twice a year to assess the herd immunity against influenza A and B viruses. Written informed consent was obtained in all cases of blood donation and further sample preparation. We used 93 remnant sera samples from herd immunity studies that were kept frozen at 80°C.

Neutralization test was performed for 365 samples that were positive for binding antibody samples and for 74 negative samples.

TCID 50 based microneutralization test (MNA) was used to detect and titrate neutralizing antibodies [20] . First, serum samples were heated for 30 min at 56°C to avoid complementlinked reduction of the viral activity. This was followed by the preparation of serial twofold dilutions starting from 1:10 in 60 uL volume (tested in triplicate) of each serum specimen in culture medium (Alpha MEM containing antibiotics and 2% heatinactivated fetal bovine serum). Each dilution was mixed at equal volume with the live SARSCoV2 virus (60 uL, containing 25 TCID 50 /50uL) and incubated for 60 minutes at 37°C in plastic microplates.

Then 100 μl of the mix was transferred into 96well microplates with monolayer Vero cells. The plates were incubated at 37°C in a 5% CO2 atmosphere. Readings were evaluated 5 to 6 days later and neutralization was recorded if 100% of the cells in the well were preserved (no visible plaques or cytopathic effect). Serum neutralizing titer was expressed as the inverse of the higher serum dilution that exhibited neutralizing activity. All experiments were performed in a BSL3 laboratory.

Clinical sensitivity was estimated with the SARSCoV2 PCR test as the gold standard and specificity in prepandemic sera sam ples. We used 46 PCR positive samples and 41 prepandemic serum samples to crossvalidate all three tests (crossvalidation sample). In the independent test validation (fullvalidation sample), different sets of nonpaired samples (60 PCR positive sam ples and 65 prepandemic samples for CMIA Abbott, 48 and 93 for ELISA VectorBest, 60 and 92 for ELISACoronapass) were 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 7, 2021. ; https://doi.org/10.1101/2021.04.05.21254712 doi: medRxiv preprint used. We report the validation study results based on the manufacturers' recommended S/CO ratios, except for CMIAAbbott, we use both the S/CO ratio of 1.4 and a more sensitive S/CO ratio of 1.0. Compared with the neutralization test results, the percent agreement (positive, negative and overall), the concordance (Cohen's Kappa coefficient along with the prevalence index (Pindex), bias index (Bindex), and prevalence and biasadjusted kappa -PABAK), and Spearman correlation coefficients were calculated [21] .

The estimates are given with the 95% confidence intervals (CI) where appropriate. R statistical software (v.4.0.2; R Founda tion for Statistical Computing, Vienna, Austria) was used for data analysis and presentation. Exact binomial confidence limits were calculated for test sensitivity, specificity, and percent agreement (negative -NPA, positive -PPA, and overall -OPA) applying the epi.tests function from the epiR package. ROC curves were constructed, and the corresponding area under the curve (AUC) was calculated for three tests using the pROC package. CIs for AUCs were calculated with 2000 bootstrap repli cates. The bootstrap test was used to compare ROC curves: a test for paired curves was used in the crossvalidation sample and nonpaired in the fullvalidation sample. Confidence intervals were calculated for Spearman's correlation with the spearmanCI package.

To report CIs for concordance measures -bias, prevalence, and kappa -we used the bootstrap percentile method (the epi.kappa function from the epiR package). Formal criteria (eg., Landis and Koch) for Cohen's Kappa interpretation were not used.

Study data and code is available online (https://github.com/eusporg/spb_covid_study20/tree/master/ validation_of_covid_tests).

The study was approved by the Research Planning Board of European University at St. Petersburg (on May 20, 2020) and the Ethic Committee of the Clinic "Scandinavia" (on May 26, 2020). All research was performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all participants of the study. The study was registered with the following identifiers: Clinicaltrials.gov (NCT04406038, submitted on May 26, 2020, date of registration -May 28,2020) and ISRCTN registry (ISRCTN11060415, submitted on May 26, 2020, date of registration -May 28,2020). The amendment, which included a test validation study, was approved by the Ethics Committee of the Clinic "Scandinavia" on October 2, 2020.

We used blood samples collected from the clinic "Scandinavia" staff as a part of the routine antibody monitoring for which the hospital obtained a separate informed consent. Additional oral consent was obtained to use collected samples for the validation study. Personal information was not linked to serum samples in the validation study except for the date of positive PCR for SARSCoV2.

Based on crossvalidation results, the sensitivity was equal to 91.1% (95% CI: 78. 8 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 7, 2021. ; https://doi.org/10.1101/2021.04.05.21254712 doi: medRxiv preprint (95% CI: 76.4-96.4). However, the sensitivity of CMIA Abbott was equal to 63.1% (95% CI 50.2-74.7). It was slightly higher with the cutoff SC/O ratio of 1.0 -70.7% (95% CI: 57.3-81.9). Specificity was equal to 100% for all the tests (see Table 1 ). Using nonpaired samples in the validation of the tests did not dramatically change the sensitivity and point estimates but narrowed confidence intervals (see Supplementary Table S1 ).

Although the comparison of ROCs for three tests has shown that AUC is lower for CMIAAbbott, the difference was not dramatic -0.96 (95% CI: 0.90-1.00) for ELISA Coronapass and 0.90 (95% CI: 0.82-0.97) for CMIA Abbott, the difference was only significant when paired samples were compared (see Table 2 and Table S2 ). The cutoff SC/O ratio of 0.28 for CMIAAbbott resulted in a sensitivity of 80% at the same full level of specificity. The other test thresholds were optimal based on the ROC analysis of crossvalidation and nonpaired samples (see Figure 1 ).

In less than onethird of the populationbased study participants with positive antibody total IgG test results, we detected neutralizing antibodies in titers 1:80 and above. NPA was between 28 Table 3 ).

The measures of concordance are presented in Table S3 . There was a moderate correlation between antibody assays results and MNA: 0.65 (95% CI: 0.59-0.71) for CMIA Abbott, 0.60 (95% CI: 0.54-0.67) for ELISA Coronapass, and 0.76 (95% CI: 0.72-0.81) for ELISA VectorBest (see Figure 2 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 7, 2021. ;  to the long period between infection and blood sampling compared to the manufacturer's validation studies (it was on average 21 weeks after the reported positive PCR test). Previous studies also found similar results for samples taken at a longer follow up [ 13; 15] . These results may also explain the decline in antibody presence in longitudinal studies that may be incorrectly interpreted by the shortterm immune response to SARSCoV2 [22] .

Based on our validation study, the Abbott Architect SARSCoV2 IgG's sensitivity can be significantly improved by incor porating a new cutoff. Moving the S/CO ratio from 1.4 or 1.0 for positivity to 0.28 improved sensitivity from 63% or 71% to 80%, respectively, without loss in specificity.

Locally available ELISA tests and Roche assays are sensitive enough to detect antibodies in most individuals with previous positive PCR tests. Tests were negative for approximately 10% of participants with positive PCR, with any antibody tests. This finding has an important practical implication. Relying on test characteristics provided by manufacturers for correction of reported prevalence estimates introduces additional bias to the study. If the test reported prevalence is 5%, then with the test sensitivity of 65% and specificity of 100%, the true prevalence would be equal to approximately 8% [27] . If the crude prevalence based on the same test is 40%, then the true prevalence would be around 62%. The magnitude of bias in the population with a significant proportion of individuals with antibodies would limit the ability to detect herd immunity threshold.

This study has several limitations. PCR test results that were chosen as a golden standard, were carried out in different laboratories. Although official test certificates that are registered in the national database were provided, falsepositive results cannot be ruled out [28] . But as mentioned above, PCR falsepositivity is likely to underestimate antibody test sensitivity in this study. Neutralization test results should be considered with caution as well [29] . Such tests can be considered as a surrogate marker of protection from reinfection, but this association needs to be explored in populationbased epidemiological studies [15] .

In conclusion, this validation study provides a reference that can be used in further seroprevalence reports to correct the results based on test sensitivity and specificity. Choice of the test for longitudinal surveillance is critical for making conclusions about the spread of SARSCoV2 and the durability of the immune response. Local tests should be rigorously evaluated for seroprevalence studies because the benefits of using properly validated tests are not only financial or related to matters of convenience. They may provide more accurate and unbiased assessments for the course of the pandemic. 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 7, 2021. ; 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 7, 2021. 

The paramount importance of serological surveys of SARSCoV2 infection and immunity

Humoral immune response to SARSCoV2 in Iceland

Prevalence of SARSCoV2 in Spain (ENECOVID): a nationwide, populationbased seroepi demiological study

Estimating COVID19 antibody seroprevalence in

Analytical methods used in estimating the prevalence of HIV/AIDS from demographic and crosssectional surveys with missing data: a systematic review

Seroprevalence of SARSCoV2 antibodies in Saint Petersburg

Comparison of sixteen serological SARSCoV2 immunoassays in sixteen clinical laboratories

Stringent thresholds in SARSCoV2 IgG assays lead to underdetection of mild infections

Evaluation of diagnostic accuracy of 10 serological assays for detection of SARSCoV2 antibodies

Quantification of SARSCoV2 antibodies with eight commercially available immunoassays

An evaluation of 4 commercial assays for the detection of SARSCoV2 antibodies in a predominantly mildly symptomatic low prevalence Australian population

Two SARSCoV2 IgG immunoassays comparison and timecourse profile of antibodies response

Sixmonth antibody response to SARSCoV2 in healthcare workers assessed by virus neutralization and commercial assays

SARSCoV2 seroprevalence worldwide: a systematic review and metaanalysis. Clinical Microbiology and Infection

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. The Journal of Infectious Diseases

Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARSCoV2 infection

A comparative evaluation between the Abbott Panbio™ COVID19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV2 IgG assay

Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARSCoV2 Antibody Assays

Sensitivity and specificity of JSC VectorBest assays for immunoglobulin of different classes to SARSCoV2 [Tchuvstvitel'nost' i specifichnost' naborov reagentov AO «VektorBest» dlja vyjavlenija immunoglobulinov raznyx klassov k SARSCoV2

Evaluation of SARSCoV2 neutralizing antibodies using a CPEbased colorimetric live virus microneutralization assay in human serum samples

Bias, prevalence and kappa

Longevity of seropositivity and neutralizing titers among SARSCoV2 infected individuals after 4 months from baseline: a populationbased study in the province of Trento

Evolution of immune responses to SARSCoV2 in mildmoderate COVID19

COVID19 reinfection in the presence of neutralizing antibodies

Antibody status and incidence of SARSCoV2 infection in health care workers

Association of SARSCoV2 Seropositive Antibody Test With Risk of Future Infection

Exact confidence limits for prevalence of a disease with an imperfect diagnostic test

Specificity and positive predictive value of SARSCoV2 nucleic acid amplification testing in a lowprevalence setting

Establishment and validation of a pseudovirus neutralization assay for SARSCoV2. Emerging microbes & infections

We acknowledge personal support from Vitaly Nesis (Chief Executive Officer, Polymetal International, plc). We thank Alla 

The study was funded by Polymetal International plc. The main funder had no role in study design, data collection, data analysis, data interpretation, writing of the report or decision to submit the publication. 

AB, DS, DD and DSk conceived the study. AB drafted the first version of the manuscript. DD and VT performed VectorBest ELISA assays, MS performed the neutralization assays. AB, DSk, RT and OD did data analyses. All authors participated in the study design, contributed to the interpretation of data and to drafting sections of the manuscript. All authors read and approved the final manuscript.

AB reports personal fees from MSD, Biocad and AstraZeneca outside the submitted work.